Therapie von Knochenmetastasen beim Mammakarzinom – Zoledronat senkt Skelettkomplikationen osteolytischer Läsionen wirksamer als Pamidronat
G. Pecher, C. Landmann, B. Häring, C. Schmidt-Gersbach, Silke Gillessen(Institute of Oncology Research), T.M. Fliedner, R. Steinmeier, I. Eidelberg, J. Tilgner, Markus Joerger(Kantonsspital St. Gallen), M. Groettup, Jurgen von Bredow, C. Unger, C. Oehlschlegel, Michael Medinger(University Hospital of Basel), Jacob Kaneti, D. Strumberg, Ulrich Massing, Daniel Pink(Universitätsmedizin Greifswald), G. Reiss, W. Queisser, D. Behringer, P. Reichardt, Jaqueline Muniz Gerber, S. Mielke, Endre Z. Neulander, Niels Henrik Holländer(Zealand University Hospital Køge), Gabriele Schackert(University Hospital Carl Gustav Carus), Wilmosh Mermershtain, Igor Yusim, C. Laus, Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), S.B. Sobottka, Bernd Dörken(Charité - Universitätsmedizin Berlin), G. Kornek, M. E. Scheulen, M. Uppenkamp, Albrecht Kretzschmar(Roche (Switzerland)), T. Cerny, I. Gusakova, Alfred C. Feller, Ralf A. Hilger(West Cancer Center), M. Neises, K. Mross, J. Drevs
Cited by 0
Related Papers
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
|New England Journal of Medicine|2006|1k
Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.
|Journal of Clinical Investigation|1997|765